Amend the claims as follows:

1.-19. (cancelled)

20. (currently amended) A method comprising evaluating the ability of a chemical entity to associate with an I-domain of the α1 chain of the α1β1 integrin, or a complex comprising an I-domain of the α1 chain of the α1β1 integrin ~~α1-I domain~~ wherein:

(a) crystallographic coordinates of either (i) the I-domain of the α1 chain of the α1β1 integrin ~~α1-I domain~~ or (ii) a complex comprising an I-domain of the α1 chain of an α1β1 integrin ~~α1-I domain~~, are used in a fitting operation between the chemical entity and said I-domain of the α1 chain of the α1β1 integrin ~~I-domain~~ or complex comprising an I-domain of the α1 chain of an α1β1 integrin ~~thereof~~, ~~thereby obtaining~~ to obtain data related to said association; ~~and~~

(b) the degree of association between the chemical entity and either (i) the I-domain of the α1 chain of the α1β1 integrin ~~α1-I domain~~, or ~~a~~ (ii) the complex comprising an I-domain of the α1 chain of an ~~comprising an~~ α1β1 integrin ~~α1-I domain~~, is evaluated in a competition assay; and

(c) the crystallographic coordinates of the I-domain of the α1 chain of the α1β1 integrin are substantially identical to those listed in Table II herein.

21.-33. (cancelled).

34. (currently amended) A method for evaluating the binding of a composition to an an I-domain of the α1 chain of an α1β1 integrin ~~α1-I domain~~ comprising:

(a) crystallizing an I-domain of the α1 chain of an α1β1 integrin ~~α1-I domain~~ by reacting a proteolytically digested ~~α1-I domain~~ I-domain of the α1 chain of an α1β1 integrin in a buffered crystallization solvent comprising a surfactant;

(b) determining the crystal coordinates of the crystallized α1-I domain;

(c) using the crystal coordinates of the crystallized α1-I domain to identify computationally a composition which bind to the α1-I domain; and

(d) using a competition assay to assess the extent to which the composition binds to the α1-I domain; wherein the crystallographic coordinates of the I-domain of the α1 chain of the α1β1 integrin are substantially identical to those listed in Table II herein.

35. (previously presented) The method of claim 34, wherein the crystallization solvent comprises a PEG surfactant and a sodium-containing buffer and the crystallized α1-I domain is frozen before its crystal coordinates are determined.

36. (previously presented) The method of claim 34, wherein the proteolytically digested α1-I domain is in a des 1-18 form.

37. (previously presented) The method of claim 35, wherein the proteolytically digested α1-I domain is in a des 1-18 form.